{"preliminary_commentary":{"by_channel":{"x_thread":102,"youtube":62,"podcast":30,"x_video":3,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04987203\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T01:21:26.760Z","note":"Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.","passages_read":null,"text":"The commentary discusses TiNivo-2’s comparison of tivozanib plus nivolumab with tivozanib alone after prior immune-checkpoint inhibitor therapy, including trial design and treatment sequencing in metastatic renal cell carcinoma. Discussion covers whether the trial clarifies a possible distinction between PD-1 and PD-L1 rechallenge raised in relation to CONTACT-03, and the broader role of checkpoint blockade after progression. Speakers also discuss tivozanib dosing, side-effect profile, patient-reported outcomes, and whether further research on pembrolizumab rechallenge is warranted."},"name":"TiNivo-2","nct_id":"NCT04987203","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tinivo-2-nct04987203. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects with advanced RCC will receive 0.89 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug and nivolumab every 4 weeks on Day 1 of each Cycle, until disease progression or unacceptable toxicities occur, other withdrawal criteria are met, or completion of 2 years of treatment \\[for nivolumab\\] whichever occurs first.","label":"Tivozanib in Combination with Nivolumab","type":"EXPERIMENTAL"},{"description":"Subjects with advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug until disease progression or unacceptable toxicities occur, or other withdrawal criteria are met.","label":"Tivozanib","type":"EXPERIMENTAL"}],"collaborators":["Parexel","Bristol-Myers Squibb"],"completion_date":{"date":"2026-01-20","type":"ACTUAL"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":343,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tivozanib","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-08","lead_sponsor":"AVEO Pharmaceuticals, Inc.","official_title":"TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression free survival","timeFrame":"Until progressive disease [PD] (Approximately 30 months)"}],"references":[{"citation":"Choueiri TK, Albiges L, Barthelemy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet. 2024 Oct 5;404(10460):1309-1320. doi: 10.1016/S0140-6736(24)01758-6. Epub 2024 Sep 13.","pmid":"39284329","type":"DERIVED"},{"citation":"Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18.","pmid":"35304832","type":"DERIVED"}],"start_date":{"date":"2021-09-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT04987203"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tinivo-2-nct04987203"}